Development of Novel Organometallic Compounds as Antibiotics
Ken Cornell, Ph.D.
Antimicrobial resistance is an emerging healthcare problem. More than 2.8 million cases of antibiotic-resistant infections are reported each year in the U.S., and the emergence of new antibiotic-resistant microbes is a growing concern. Most scientific research is focused on the exploration and development of common antibiotics, but the search for new drug compounds is a necessity. Organometallic compounds are a class of drugs that have largely been overlooked in antibiotic research. These compounds have unique structures that have an impact on microbial growth. In this study, a series of organometallic compounds were first studied using Kirby-Bauer disk diffusion assays. The compounds were further analyzed using microdilution assays. The half maximal inhibitory concentration (IC50) and Minimum Inhibitory Concentration (MIC) were determined for all organometallic compounds. The results of this study showed that this series of organometallic compounds are effective against Gram-positive bacteria and organometallic compounds with silver ion complexes showed greater inhibition and broader susceptibility profiles overall.
Leach, Caleb; Lusk, Kyle; Williams, Ashley; Koch, Taylor; Belhadj, Sarrah; Waynant, Kris; and Cornell, Ken, "Development of Novel Organometallic Compounds as Antibiotics" (2021). 2021 Undergraduate Research Showcase. 145.